Treatment News : Test-and-Treat Has Cost Versus Benefit Considerations - by Laura Whitehorn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
E-newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » July 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

July 24, 2012

Test-and-Treat Has Cost Versus Benefit Considerations

by Laura Whitehorn

AIDS 2012Where financial resources are limited, targeting groups at high risk for HIV infection for testing and immediate treatment is more cost effective than a community-wide test-and-treat initiative, according to New York City modeling data presented Monday, July 23, at the XIX International AIDS Conference in Washington, DC.

Public health initiatives are moving away from risk-based testing to identify people in need of care and antiretroviral (ARV) therapy and now beginning to focus on testing all adults living with HIV in the general population, said Jason Kessler, MD, of New York University School of Medicine, the lead author of the presented research. Whether or not this should be a priority in areas where the resources may be limited in terms of providing adequate care and support for people found to be living with the virus remains a matter of controversy.

TLC-Plus is a test-and-treat initiative being evaluated in HIV Prevention Trials Network study 065 (HPTN 065), currently under way in New York City and Washington, DC. It involves community-wide HIV testing and, for those found to be positive for the virus, linkage to care, immediate treatment and supportive services.

Kessler and his colleagues at the New York City Department of Health and Mental Hygiene used statistical modeling to determine the usefulness and cost-effectiveness of TLC-Plus, executed according to its original design or modified to focus primarily on populations at high risk for HIV infection (e.g., men who have sex with men and/or injection drug users).

Over a 20-year period, Kessler and his colleagues estimated that there would be roughly 59,000 new HIV infections in New York City in the absence of TLC-Plus.

TLC-Plus with immediate ARV therapy could avert 20 percent of these infections in New York City—roughly 47,600 new infections, down from 59,000—provided that it is implemented in the general population of city residents.

More “focused” prioritization, the researchers’ modeling found, resulted in fewer infections averted overall. Prioritization to populations at higher risk for HIV transmission and or acquisition, Kessler explained, only retained 14 to 68 percent of the overall effect.

These compromises, however, came with reduced total costs and cost-per-infection averted. Whereas the cost-per-infection averted would be more than $1.5 million under the general community roll-out of TLC-Plus, a roll-out of TLC-Plus targeting high-risk individuals would come with a cost-per-infection averted of $360,000.

“Without consideration of costs it makes most sense to roll [TLC-Plus] out to as many people as you can possibly reach,” Kessler said. “When you bring cost into the equation—you want to optimize the bang for your buck—it makes the most sense to prioritize your intervention on the highest risk groups.”

Given limited budgets, he concluded, the analysis favors targeting high-prevalence populations and neighborhoods for TLC-Plus.

Search: tlc-plus, hiv, test and treat, treatment, prevention, new york city, cost, benefit, kessler, aids 2012


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Join POZ Facebook Twitter Google+ MySpace YouTube Tumblr Flickr
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dave41
    Bethany
    Oklahoma


    soy_Ric
    Rochester
    New York


    jimmy807
    San Antonio
    Texas


    albsur7436
    San Francisco
    California
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.